A drug designed to improve memory formation is now recruiting early-stage Alzheimer’s patients in 60 areas around the country for a Phase II clinical…
Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two…
Heidi V. Pickett and David Weild weigh in on the financial obstacles that have stymied progress in Alzheimer’s drug development. Last month, Roche announced…
What if you could get an Alzheimer’s vaccine like you do for measles or chickenpox? Scientists at University of Texas Southwestern Medical Center are…